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Abstract
AIM: To evaluate the possibility of treatment effect 
monitoring using hepatic fat quantification magnetic 
resonance (MR) in pediatric nonalcoholic steatohepatitis 
(NASH). 
METHODS: We retrospectively reviewed the medical 
records of patients who received educational recom-
mendations and vitamin E for NASH and underwent 
hepatic fat quantification MR from 2011 to 2013. 
Hepatic fat fraction (%) was measured using dual- and 
triple-echo gradient-recalled-echo sequences at 3T. The 
compliant and non-compliant groups were compared 
clinically, biochemically, and radiologically. 
RESULTS: Twenty seven patients (M:F = 24:3; mean 
age: 12 ± 2.3 years) were included (compliant group = 
22, non-compliant = 5). None of the baseline findings 
differed between the 2 groups, except for triglyceride 
level (compliant vs  non-compliant, 167.7 mg/dL vs  
74.2 mg/dL, P  = 0.001). In the compliant group, high-
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density lipoprotein increased and all other parameters 
decreased after 1-year follow-up. However, there were 
various changes in the non-compliant group. Dual-
echo fat fraction (-19.2% vs  4.6, P  < 0.001), triple-
echo fat fraction (-13.4% vs  3.5, P  < 0.001), alanine 
aminotransferase (-110.7 IU/L vs  -10.6 IU/L, P  = 
0.047), total cholesterol (-18.1 mg/dL vs  3.8 mg/dL, P  
= 0.016), and triglyceride levels (-61.3 mg/dL vs  11.2 
mg/dL, P  = 0.013) were significantly decreased only in 
the compliant group. The change in body mass index 
and dual-echo fat fraction showed a positive correlation 
(ρ = 0.418, P  = 0.030).
CONCLUSION: Hepatic fat quantification MR can be a 
non-invasive, quantitative and useful tool for monitoring 
treatment effects in pediatric NASH.
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Core tip: Few noninvasive methods have been evaluated 
to accurately assess and monitor the progression of 
nonalcoholic steatohepatitis (NASH) in children. In this 
study, we used hepatic fat quantification magnetic 
resonance (MR) and compared the compliant and non-
compliant groups for treatment of pediatric NASH. 
The compliant group showed not only laboratory 
improvement but also a decrease in the fat fraction in 
both dual- and triple-echo sequences after follow-up. 
Therefore, hepatic fat quantification MR can be a non-
invasive, quantitative and useful tool for monitoring 
treatment effects in pediatric NASH.
Koh H, Kim S, Kim MJ, Kim HG, Shin HJ, Lee MJ. Hepatic 
fat quantification magnetic resonance for monitoring treatment 
response in pediatric nonalcoholic steatohepatitis. World J 
Gastroenterol 2015; 21(33): 9741-9748  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i33/9741.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i33.9741
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most 
common cause of chronic liver disease in children and 
adolescents[1-3]. It varies in severity from simple fatty 
liver to nonalcoholic steatohepatitis (NASH), which may 
induce hepatic fibrosis, cirrhosis, and hepatocellular 
carcinoma[4,5]. Cirrhosis due to NAFLD has already 
been reported in 2 boys aged 10 and 14 years[6]. 
Therefore, prompt diagnosis and suitable treatment 
are mandatory. Proper diet, exercise, and vitamin E 
may help improve steatosis in liver histology[7-10].
Liver biopsy is the modality of choice to accurately 
diagnose NAFLD and to monitor disease progression 
during treatment, even in children and adolescents. 
However, this procedure is invasive and may result 
in life-threatening complications[11,12]. In addition, it 
has many drawbacks, including sampling error and 
inter- and intra-observer variability in interpretation. 
Liver biopsy can also be associated with complications 
such as abdominal pain, hypotension, hemobilia, and 
intraperitoneal hemorrhage, the last of which has an 
associated mortality rate of up to 0.5%. Furthermore, 
liver biopsy is not generally accepted by patients 
and especially not by children and adolescents[13-15]. 
Therefore, there is a need to develop noninvasive 
methods to accurately assess and monitor the pro-
gression of NAFLD in children. 
Various imaging studies can be used for the 
noninvasive assessment of hepatic fat including 
ultrasonography, computed tomography (CT), and 
magnetic resonance (MR) imaging. Ultrasonography 
can detect fatty liver as increased liver parenchymal 
echogenicity. There is no risk of radiation exposure 
using this method. However, its ability to grade 
the fatty liver in children is limited[5], despite an 
attempt to quantitatively analyze hepatic fat with 
ultrasonography[16]. Moreover, positive ultrasonographic 
results in severely obese adolescents cannot be used 
to accurately predict the presence and severity of 
hepatic steatosis[17]. 
CT can also detect hepatic fat infiltration by 
analyzing hepatic parenchymal attenuation[18]. 
However, hepatic attenuation can also be affected by 
other conditions such as hemosiderin deposition[19]. 
Moreover, the risk of radiation exposure is a major 
disadvantage, especially in children. No studies have 
yet compared the CT assessment of hepatic steatosis 
with histologic grades of fatty infiltration in children[5]. 
Both MR imaging and MR spectroscopy can detect 
hepatic fat infiltration simply and accurately without 
radiation exposure[20], even though MR spectroscopy 
needs a long examination time for a small volume 
of the liver. When using MR imaging, quantitative 
measurement of the fat fraction using a chemical shift 
technique, which distinguishes resonant frequencies 
between fat and water, can easily evaluate fat in the 
liver. In addition, it can be obtained using the dual- or 
triple-echo gradient recalled-echo sequences, which 
can be used easily and quickly in children[21]. However, 
there is limited information regarding the utility of 
hepatic fat quantification MR in children with NASH, 
and no studies have used this technique to monitor 
treatment effects in these patients. Therefore, the 
purpose of this study was to evaluate the possibility of 
treatment monitoring with hepatic fat quantification 
MR as a non-invasive and quantitative method in 
pediatric NASH. 
MATERIALS AND METHODS
Patients
This retrospective study was approved by the Insti-
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tutional Review Board of our hospital (1-2014-0007) 
and the acquisition of informed consent for review of 
patients’ images and medical records was waived. We 
declare that none of the authors of the present study 
has any competing commercial, personal, political, 
intellectual or religious interest with respect to the 
present study. We reviewed the medical records of 
27 pediatric patients referred for NASH between 
January 2011 and December 2013. Diet and a physical 
exercise education program for the reduction of body 
weight were provided carefully and continuously to all 
patients. A low-calorie diet (25-30 kcal/kg per day) 
composed of specified quantities of fat (25%-30%), 
carbohydrate (50%-60%) and protein (15%-20%) 
was recommended. Clinical nutritionists in our hospital 
guided the diet planning and a moderate exercise 
program (1 h/d at least 5 d a week). Vitamin E (daily 
dose 800 IU) was also recommended to all patients 
to improve liver histology[22]. Compliance with the 
diet and exercise treatment regime was checked at 
every clinic visit from daily records about feeding, 
exercise, and medication history written by parents 
and caregivers. Treatments other than diet, physical 
exercise education, and vitamin E were not provided. 
Sex, age at the time of diagnosis, body weight, body 
mass index (BMI), and laboratory data were collected. 
Hepatic fat quantification MR was performed at the 
initial referral and 1 year later for follow-up. We 
reviewed body weight, BMI, and laboratory results 
at the time of MR acquisition. Laboratory results 
included aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), total bilirubin, albumin, 
alkaline phosphatase (ALP), cholesterol, triglycerides, 
high density lipoprotein (HDL), and low density 
lipoprotein (LDL) levels. 
Hepatic fat quantification MR
We retrospectively reviewed hepatic fat quantification 
MR of NASH patients. The hepatic fat fraction (%) 
was measured using dual- and triple-echo gradient-
recalled-echo sequences on a 3T MR system (Tim Trio; 
Siemens Medical Solutions, Erlangen, Germany) with 
a phased body array coil. For dual-echo chemical-shift 
gradient-echo MR, we obtained axial images of the 
liver using gradient echo T1-weighted, dual-echo, in-
phase, and opposed-phase sequences [TR 226 ms; 
TE 1.23 (opposed-phase) and 2.46 (in-phase) ms; flip 
angle 65°; section thickness 6 mm; matrix size 192 × 
256; and field of view 300 cm × 400 cm]. For triple-
echo MR, the imaging protocol included a breath-
hold low-flip-angle T1-weighted, triple-echo, spoiled 
gradient-echo sequence [TR 226 ms; TE 2.46 (in-phase 
1), 3.69 (opposed-phase), and 4.92 (in-phase 2) ms; 
flip angle 20°; section thickness 6 mm; matrix size 
256 × 192; and field of view 315 cm × 420 cm].
One radiologist (Lee MJ), who had 10 years’ 
experience in pediatric radiology, randomly drew 2 
regions of interest (ROIs) that avoided hepatic vessels 
in the homogenous parenchyma of the right hepatic 
lobe on a picture archiving and communication system 
(Centricity, General Electric Corporation, Milwaukee, WI, 
United States). The reviewer obtained signal intensity at 
the same level of in-phase (IP) and opposed-phase (OP) 
images. The hepatic fat fraction in dual-echo MR was 
calculated from the following equation: Dual-echo fat 
fraction (%) = [(IP-OP)/(2 × IP)] × 100[23].
Theoretically, three ROIs should be obtained with 
the same method used to measure the triple-echo fat 
fraction. The signal intensities can be obtained at the 
same level IP1, OP, and IP2 images. The hepatic fat 
fraction in triple-echo MR can be calculated from the 
equation as follows: Triple-echo fat fraction (%) ≤ 
[(IP1 + IP2)/2 - OP]/(IP1 + IP2) > × 100[24].
In our workstation, the triple-echo fat fraction was 
automatically calculated and we obtained a triple-echo 
fat map for direct fat fraction measurement in a single 
ROI. 
Statistical analysis
Patients who followed the educational recommendations 
and showed marked changes in BMI, AST, and ALT 
over 1 year under observation were defined as the 
compliant group. Patients who did not follow the 
recommendations well were defined as the non-
compliant group. Statistical analysis was performed 
using SPSS version 20.0.0 (IBM Corp., Armonk, NY, 
United States). We compared clinical, biochemical, 
and radiological parameters between the compliant 
group and the non-compliant group. Continuous 
variables, including age, body weight, BMI, laboratory 
results, and hepatic fat fractions on MR, were analyzed 
with the Mann-Whitney U test. The difference in sex 
between the 2 groups was analyzed using Fisher’s 
exact test. To compare the results of the initial study 
with 1 year follow-up, the Wilcoxon signed-rank test 
was used. Spearman correlation analysis between 
body weight or BMI change and fat fraction change 
measured on MR was also performed. P values < 0.05 
were considered statistically significant. The statistical 
methods of this study were reviewed by Ha Yan Kim 
from Biostatistics Collaboration Unit, Yonsei University 
College of Medicine.  
RESULTS
Baseline findings
Twenty seven children with NASH underwent fat 
quantification MR during the study period. All children 
underwent both a pre-treatment and a follow-up MR 
and were included in this study. There were 24 boys 
and 3 girls, with a mean age of 12.0 ± 2.3 years (range, 
9-19 years). There were 22 patients (81.5%) in the 
compliant group and 5 (18.5%) in the non-compliant 
group. Table 1 demonstrates the baseline findings in all 
children. There were no significant differences between 
the groups except for the triglyceride level, which was 
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and triple-echo fat fractions were decreased in the 
compliant group (P < 0.001) (Figure 1). The mean 
initial hepatic fat fraction was 34.9% on dual-echo 
MR and 23.6% on triple-echo MR, and it decreased to 
15.8% on dual-echo MR and to 10.1% on triple-echo 
MR in the compliant group. The follow-up MR showed 
increased mean fat fraction in the non-compliant group 
on both dual-echo MR (from 31.3% to 35.9%, P > 
0.05) and triple-echo MR (from 19.5% to 22.9%, P > 
0.05) (Figure 2). 
The 2 groups differed in both dual-echo fat fraction 
(-19.2% vs 4.6%, P < 0.001) and triple-echo fat 
fraction (-13.4% vs 3.5%, P < 0.001), with a decreased 
fat fraction observed only in the compliant group. 
Among the laboratory results, ALT (-110.7 IU/L vs -10.6 
IU/L, P = 0.047), cholesterol (-18.1 mg/dL vs 3.8 mg/
dL, P = 0.016), and triglycerides (-61.3 mg/dL vs 11.2 
higher in the compliant group (167.7 mg/dL) than in 
the non-compliant group (74.2 mg/dL) (P = 0.001). 
Comparison of changes in the 2 groups at 1-year follow-
up
Table 2 shows the results of the initial and follow-up 
findings in the 2 groups. Body weight did not change 
significantly in either group. However, BMI decreased 
only in the compliant group (from 28.8 kg/m2 to 26.3 
kg/m2, P = 0.016). Almost all laboratory results except 
albumin and ALP changed significantly during follow-
up in the compliant group. AST, ALT, cholesterol, 
triglycerides, and LDL decreased, and HDL increased 
in the compliant group, which reflected the treatment 
effect. However, no laboratory results changed during 
follow-up in the non-compliant group. 
On hepatic fat quantification MR, both dual- 
9744 September 7, 2015|Volume 21|Issue 33|WJG|www.wjgnet.com
Table 1  Baseline characteristics of all patients, and comparison between the compliant and non-compliant groups
All children (n  = 27) Compliant group (n  = 22) Non-compliant group (n  = 5) P  value1
Demographics Male, n (%) 24 (88.9) 20 (90.9) 4 (80.0) NS
Age (yr) 12.0 ± 2.3 11.8 ± 1.9 12.8 ± 3.7 NS
B.wt (kg)   66.2 ± 16.0   65.4 ± 16.5   70.0 ± 14.5 NS
BMI (kg/m2) 26.6 ± 3.4 28.8 ± 3.6 25.9 ± 2.5 NS
Laboratory findings AST (IU/L)   79.9 ± 79.4   83.0 ± 85.8   66.0 ± 44.0 NS
ALT (IU/L)   138.7 ± 112.0   148.6 ± 119.2   95.2 ± 63.7 NS
T.Bil (mg/dL)   0.6 ± 0.3   0.6 ± 0.3   0.6 ± 0.3 NS
Albumin (g/dL)   4.6 ± 0.2   4.6 ± 0.2   4.5 ± 0.2 NS
ALP (IU/L) 208.6 ± 77.3 210.5 ± 73.8   200.4 ± 100.8 NS
Cholesterol (mg/dL) 187.9 ± 30.0 192.6 ± 30.0 167.0 ± 21.0 NS
TG (mg/dL) 150.4 ± 74.1 167.7 ± 71.1   74.2 ± 16.4 0.001
HDL (mg/dL) 45.0 ± 8.3 44.9 ± 9.0 45.2 ± 4.7 NS
LDL (mg/dL) 120.5 ± 30.3 123.3 ± 32.0 108.0 ± 18.5 NS
Hepatic fat fraction 
on MR
Dual-echo sequence (%) 34.2 ± 8.5 34.9 ± 8.2 31.3 ± 9.8 NS
Triple-echo sequence (%) 22.8 ± 7.3 23.6 ± 7.2 19.5 ± 7.4 NS
1Comparison between the compliant and non-compliant groups using the Mann-Whitney U test, except for gender, which was compared using Fisher’s exact 
test. All data show mean ± standard deviation. B.wt: Body weight; BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; 
T.Bil: Total bilirubin; ALP: Alkaline phosphatase; TG: Triglyceride; HDL: High density lipoprotein; LDL: Low density lipoprotein; NS: Not significant. 
Table 2  Comparison of clinical outcomes between initial diagnosis and 1 year after referral
Compliant group (n  = 22) Non-compliant group (n  = 5)
Initial After 1 yr P -value1 Initial After 1 yr P  value1
Male, n (%) 20 (90.9) 4 (80.0)
Age (yr) 11.8 ± 1.9 12.8 ± 3.7
B.wt (kg)   65.4 ± 16.5   67.3 ± 14.7 NS   70.0 ± 14.5   72.3 ± 15.0 NS
BMI (kg/m2) 28.8 ± 3.6 26.3 ± 3.4 0.016 25.9 ± 2.5 26.4 ± 2.7 NS
AST (IU/L)   83.0 ± 85.8   29.2 ± 20.0 0.002   66.0 ± 44.0   50.0 ± 37.5 NS
ALT (IU/L)   148.6 ± 119.2   37.9 ± 41.8 < 0.001   95.2 ± 63.7   84.6 ± 63.5 NS
T.Bil (mg/dL)   0.6 ± 0.3   0.7 ± 0.4 0.015   0.6 ± 0.3   0.70 ± 0.37 NS
Albumin (g/dL)   4.6 ± 0.2   4.6 ± 0.3 NS   4.5 ± 0.2   4.70 ± 0.30 NS
ALP (IU/L) 210.5 ± 73.8 202.1 ± 93.5 NS   200.4 ± 100.8 153.6 ± 71.6 NS
Cholesterol (mg/dL) 192.6 ± 30.0 174.5 ± 28.2 0.001 167.0 ± 21.0 170.8 ± 22.5 NS
TG (mg/dL) 167.7 ± 71.1 106.4 ± 39.8 < 0.001   74.2 ± 16.4   85.4 ± 20.1 NS
HDL (mg/dL) 44.9 ± 9.0 48.4 ± 9.6 < 0.001 45.2 ± 4.7 46.0 ± 4.5 NS
LDL (mg/dL) 123.3 ± 32.0 100.3 ± 26.3 < 0.001 108.0 ± 18.5 105.0 ± 30.8 NS
Dual-echo sequence (%) 34.9 ± 8.2 15.8 ± 8.2 < 0.001 31.3 ± 9.8 35.9 ± 8.9 NS
Triple-echo sequence (%) 23.6 ± 7.2 10.1 ± 4.6 < 0.001 19.5 ± 7.4 22.9 ± 5.6 NS
1Comparison between initial and 1-year follow-up in the 2 groups using the Wilcoxon signed-rank test. All data show mean ± standard deviation.
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mg/dL, P = 0.013) differed between the 2 groups.
In the correlation analysis which included all 
patients, the BMI change and the dual-echo fat fraction 
change showed a positive correlation (ρ = 0.418, P 
= 0.030). However, the BMI change and triple-echo 
fat fraction change was not correlated (ρ = 0.316, P 
= 0.109). The body weight change and fat fraction 
change also did not show a significant correlation in 
both dual-echo (ρ = 0.213, P = 0.285) and triple-echo 
(ρ = 0.135, P = 0.501) sequences. 
DISCUSSION
Dual- and triple-echo gradient recalled-echo sequences 
can easily perform noninvasive assessment and 
quantitative measurement of hepatic fat, even in 
children. Our study demonstrated that not only clinical 
and laboratory results but also fat fraction on MR 
improved in children with good treatment compliance. 
These results suggest the possible usefulness of fat 
quantification MR as a noninvasive and quantitative 
tool for monitoring treatment effects in children with 
NASH. 
Ultrasonography is the favored method for eva-
luating hepatic disease in children because results 
are easily obtainable and it is noninvasive. Disturbed 
propagation of ultrasound waves can occur when 
there are lipid droplets within hepatocytes[5]. This 
causes the scattering of the waves, which creates 
more returning echoes to the transducer. Therefore, 
we can qualitatively determine fatty infiltration in 
the liver when the liver parenchymal echogenicity is 
increased when compared with the kidney. Shannon 
et al[16] performed a cohort study of pediatric patients 
with biopsy-proven NAFLD and demonstrated 
excellent correlation between the ultrasonographic 
steatosis score and the histologic grade of steatosis. 
However, Bohte et al[17] showed the limitations of 
ultrasonography in severely obese adolescents 
when evaluating the severity of hepatic steatosis. In 
addition, a recent systemic review for imaging liver fat 
in children concluded that ultrasonography had a low 
positive predictive value of 47%-62% for the diagnosis 
of fatty liver[5]. 
MR imaging is one of the most sensitive tools used 
to evaluate fat infiltration in the liver. Both MR imaging 
and MR spectroscopy can accurately and reproducibly 
measure hepatic fat[25]. However, MR spectroscopy 
evaluates only a small portion of the liver and requires 
a long examination time and expertise for data 
acquisition and analysis[23,25]. When using MR imaging, 
the degree of fat infiltration can be estimated by using 
chemical shift imaging[20]. The term chemical shift 
refers to the difference in precessional (or resonance) 
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Figure 1  Liver fat quantification magnetic resonance in an 11-year-old boy in the compliant group. The same circular regions of interest (white circles) are 
drawn to measure signal intensity in the liver parenchyma. On initial magnetic resonance (MR) images (A-C), signal intensity of the liver is 56.6 on the opposed-phase 
image (A) and 725.4 on the in-phase image (B). Therefore, the calculated fat signal percentage in the liver on the dual-echo sequence is 46% [(725.4-56.6) × 100/2 
× 725.4]. The fat signal percentage in the liver is 34.4% on the fat map image (C) of the triple-echo sequence. On follow-up liver MR after treatment (D-F), hepatic 
signal intensity is 331.1 on the opposed-phase image (D) and 617.8 on the in-phase image (E), with a calculated fat signal percentage of 23% [(617.8-331.1) × 100/2 
× 617.8] on the dual-echo sequence. The triple-echo sequence image also demonstrates a decreased hepatic fat signal percentage of 15% on the fat map image (F).
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frequency between 2 proton MR signals, expressed 
in parts per million of the resonance frequency of 
the static magnetic field B0. This technique uses 
differences in the resonance frequencies of water and 
lipids to differentiate tissues containing only water 
from those containing both water and lipids[5]. The 
characteristic resonance frequencies of fat and water 
and the detection of a fat-specific frequency allows 
for quantitative measurement of hepatic steatosis. 
Therefore, while normal liver parenchyma exhibits 
similar signal intensity on IP and OP images, the fatty 
liver shows diminished signal intensity on OP images, 
as seen in our study. 
The dual-echo technique is available on most 
clinical imagers with a field strength of 1.0T or higher. 
We can obtain both IP and OP images after a single 
radiofrequency excitation using this technique, allowing 
rapid acquisition of images during a single breath 
hold[23]. There are many reports about the utility of this 
technique in evaluating hepatic steatosis in adults[26]. 
However, there is only one report of the dual-echo 
technique being performed in children. In 2011, 
Pacifico et al[21] demonstrated a strong correlation 
between the dual-echo MR fat fraction and the 
histologic grade of hepatic steatosis among 25 children 
with NAFLD. No studies have yet evaluated the utility 
of this technique for monitoring treatment effects in 
children with NASH. This is the first study detecting 
longitudinal changes in hepatic fat in pediatric NASH, 
even though we did not perform histologic correlation 
as biopsy is not considered a proper method for 
treatment monitoring, especially in children. We 
demonstrated that not only clinical and laboratory 
results but also fat fraction on MR improved in children 
with good treatment compliance. We also showed that 
the BMI change and the dual-echo fat fraction change 
had a positive correlation. Therefore, the dual-echo 
technique can be a useful monitoring tool in children 
with fatty liver disease.
Triple-echo MR imaging is somewhat similar to dual-
echo MR imaging. However, the triple-echo technique 
acquires a second IP image in addition to the first OP 
and IP images. The signal intensities of the first OP and 
IP images are corrected for the T2* effect using the 
T2* time estimated from the signal decay between the 
first and second IP images[25]. The dual-echo technique 
cannot correct for potentially confounding T2* 
relaxation effects, which should considered in cases 
with elevated liver iron content, such as cirrhosis and 
hemochromatosis[23,27]. Qayyum et al[28] demonstrated 
that fat quantification determined with chemical shift 
imaging correlated better with the histopathologically 
determined percentage of fat in non-cirrhotic patients 
compared with cirrhotic patients. 
Several recent reports evaluated the triple-echo 
technique for quantification of hepatic steatosis in 
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Figure 2  Liver fat quantification magnetic resonance in a 12-year-old girl in the non-compliant group. The same circular regions of interest (white circles) are 
drawn to measure signal intensity in the liver parenchyma. On initial MR images (A-C), signal intensity of the liver is 299.1 on the opposed-phase image (A) and 644.6 
on the in-phase image (B). Therefore, the calculated fat signal percentage in the liver on the dual-echo sequence is 26.8% [(644.6-299.1) × 100/2 × 644.6]. The fat 
signal percentage in the liver is 16.6% on the fat map image (C) of the triple-echo sequence. On follow-up liver MR after treatment (D-F), the fat signal is 238.6 on the 
opposed-phase image (D) and 750.6 on the in-phase image (E), with a calculated fat signal percentage of 34.1% [(750.6-238.6) × 100/2 × 750.6] on the dual-echo 
sequence. The triple-echo sequence image also demonstrates an increased hepatic fat signal percentage of 20.4% on the fat map image (F). 
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adults[29,30]. Hwang et al[29] demonstrated a correla-
tion between both triple-echo MR imaging and MR 
spectroscopy with macrovesicular steatosis. They 
suggested cutoff values of 4.93% and 5.79% for the 
detection of substantial macrovesicular steatosis for 
both techniques, respectively, without a significant 
difference. Wu et al[30] compared dual-echo MR, triple-
echo MR, and MR spectroscopy for the evaluation 
of hepatic steatosis and found that triple-echo MR 
imaging had the highest correlation. However, no 
studies evaluated triple-echo MR imaging in children 
with NASH. Our study demonstrated that both 
the dual-echo and triple-echo techniques showed 
a significant decrease in hepatic fat fraction after 
treatment. The mean fat fraction decreased from 
34.9% to 15.8% with the dual-echo sequence and 
from 23.6% to 10.1% with the triple-echo sequence in 
the compliant group. However, we could not evaluate 
the effect of hepatic iron content or fibrosis between 
the 2 sequences in these patients. Further study is 
required to compare the accuracy of these sequences 
in children with NAFLD.
Our study has several limitations. First, diagnosis 
and improvement during NASH follow-up were not 
proven pathologically. We could not directly correlate 
or compare the MR fat fraction with histologic grades of 
fatty infiltration. We also could not evaluate or consider 
hepatic fibrosis in our patients. However, liver biopsy 
is not a routine examination in children with NASH 
and is not appropriate for treatment monitoring. The 
second limitation was the small number of patients 
with a short-term follow-up period. We included 
only children with NASH who underwent both a pre-
treatment and a 1-year follow-up MR for hepatic fat 
quantification during the study period. Even though 
all children in the compliant group showed decreased 
hepatic fat fraction on both sequences in this short 
period of follow-up, long-term monitoring is mandatory 
in these patients. Additional prospective studies with a 
large number of children and long-term follow-up are 
needed to validate our results. The third limitation was 
that chemical shift MR imaging cannot differentiate the 
water dominant and fat dominant liver[23]. In fact, this 
technique cannot evaluate a fatty liver with more than 
a 50% fat component. However, a hepatic fat fraction 
of more than 50% is rare; in a study of over 2000 
patients by Szczepaniak et al[31], no patients had a fat 
fraction exceeding 50%. Therefore, this may be only a 
theoretical concern. 
In conclusion, hepatic fat quantification MR can be a 
useful tool to non-invasively and quantitatively monitor 
treatment effects in pediatric NASH. Furthermore, 
it can also help reduce the number of unnecessary 
biopsies in these patients. 
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